---
title: "Dianthus Maintained at Buy as Strong Cash Runway and DNTH312 Pipeline Potential Support Unchanged $125 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294877422.md"
description: "LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Dianthus Therapeutics with an unchanged $125 price target. The decision is supported by the company's strong balance sheet, featuring approximately $1.2 billion in cash extending its runway to 2030, eliminating near-term financing risks. Additionally, the newly disclosed DNTH312 pipeline asset is viewed as strategically important due to its best-in-class potential and broad applicability in neuromuscular and autoimmune diseases."
datetime: "2026-08-04T21:45:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294877422.md)
  - [en](https://longbridge.com/en/news/294877422.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294877422.md)
generator: "portal-rs"
---

# Dianthus Maintained at Buy as Strong Cash Runway and DNTH312 Pipeline Potential Support Unchanged $125 Price Target

Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Dianthus Therapeutics and keeping the price target at $125.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Rami Katkhuda has given his Buy rating due to a combination of factors, including Dianthus’s exceptionally strong balance sheet and extended cash runway. With roughly $1.2B in cash and equivalents projected to fund operations into 2030, the company is positioned to advance its pipeline without near‑term financing risk, supporting the unchanged $125 price target.

He also views the newly disclosed DNTH312 as a strategically important asset that reinforces the growth story. DNTH312’s bifunctional design—combining potent classical complement inhibition with BAFF/APRIL targeting—offers best‑in‑class potential and broad neuromuscular and autoimmune applicability, which, together with Claseprubart’s ongoing development, underpins his expectation for meaningful long‑term value creation in DNTH.

### Related Stocks

- [DNTH.US](https://longbridge.com/en/quote/DNTH.US.md)

## Related News & Research

- [Dianthus EVP, Head of R&D Simrat Randhawa sells USD 2.45 million in common shares](https://longbridge.com/en/news/297955899.md)
- [Apalach Current Reaches 2,000 Subscribers as Independent Newsletter Expands Coverage of Florida’s Forgotten Coast](https://longbridge.com/en/news/298468032.md)
- [Saga Communications declares quarterly cash dividend of $0.25 a share](https://longbridge.com/en/news/298639640.md)
- [CCOI Deadline Alert: SueWallSt Reminds COGENT COMMUNICATIONS HOLDINGS, INC. (CCOI) Investors of Securities Class Action Deadline on September 21, 2026](https://longbridge.com/en/news/298609919.md)
- [REG - State Street Global Gamma Communications - Form 8.3 - Gamma Communications plc](https://longbridge.com/en/news/298331080.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**